Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

Creative Commons License

Altunok E. S., SAYAN M., AKHAN S., AYGEN B., YILDIZ O., Koruk S. T., ...Daha Fazla

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, cilt.50, ss.1-5, 2016 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 50
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.ijid.2016.07.003
  • Dergi Adı: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1-5
  • Anahtar Kelimeler: Baseline resistance, hepatitis C virus, mutation, protease inhibitors, GENOTYPE 1, PEGYLATED INTERFERON, ANTIVIRAL AGENTS, VIRUS GENOTYPES, RIBAVIRIN, TELAPREVIR, SIMEPREVIR, INFECTION, POLYMORPHISMS, RETREATMENT
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals.